Management of Gestational Diabetes Mellitus – Evidence‑Based Guideline Summary

Lifestyle Management

• 70–85 % of women with gestational diabetes achieve glycemic control using medical nutrition therapy and physical activity alone. The Fifth International Workshop‑Conference on Gestational Diabetes Mellitus recommends initiating treatment with lifestyle modifications before pharmacologic therapy. [1][2]
• All patients should be referred promptly to a registered dietitian nutritionist experienced in gestational diabetes for individualized meal planning. This referral improves adherence to dietary goals. [3][4]
• Minimum daily macronutrient targets are approximately 175 g of carbohydrate, 71 g of protein, and 28 g of fiber. Meeting these targets supports adequate maternal nutrition while limiting glucose excursions. 5
• In overweight or obese patients, modest reductions in total energy and carbohydrate intake are appropriate, provided starvation ketosis is avoided. Tailoring caloric restriction reduces insulin resistance without compromising fetal growth. [3][4]

Glucose Monitoring & Glycemic Targets

• Self‑monitoring of blood glucose (SMBG) should be performed fasting and post‑prandially, aiming for the following targets set by the Fifth International Workshop‑Conference on Gestational Diabetes Mellitus:
  
  • Fasting < 95 mg/dL (5.3 mmol/L)
  • 2‑hour post‑prandial < 120 mg/dL (6.7 mmol/L)
• Hemoglobin A1C alone is insufficient for monitoring glycemic control in pregnancy, because it does not capture post‑prandial spikes that drive fetal overgrowth. SMBG remains the preferred method. 1

Indications for Pharmacologic Therapy

• Add pharmacologic treatment if glycemic targets are not reached within 1–2 weeks of optimized lifestyle measures, or if ultrasound shows signs of excessive fetal growth. Early escalation prevents prolonged hyperglycemia. [3][4]

Pharmacologic Therapy

Insulin (First‑Line)

• Insulin is the recommended first‑line agent because it does not cross the placenta to a measurable extent. This minimizes direct fetal drug exposure. [2][5]
• Insulin dosing should be titrated frequently (weekly to bi‑weekly in the second trimester) as insulin resistance rises rapidly during pregnancy. Close titration improves maternal glucose control. 1

Oral Agents (Not First‑Line)

• Metformin and glyburide are not recommended as first‑line agents. Both cross the placenta (metformin to a greater degree) and lack robust long‑term safety data for offspring. [2][5]
• Failure rates are notable: glyburide fails to achieve targets in ~23 % of women, while metformin fails in 25–28 % of cases. 2
• Glyburide use is linked to higher rates of neonatal hypoglycemia and macrosomia compared with insulin therapy. This underscores the safety advantage of insulin. 2

Fetal and Maternal Surveillance

• Serial ultrasound assessment of fetal growth, particularly abdominal circumference, should be performed to identify excessive growth that may warrant treatment intensification. Early detection guides timely therapeutic adjustments. 3
• Blood pressure and urinary protein should be measured at every prenatal visit, given the increased risk of hypertensive disorders in gestational diabetes. Routine screening enables early intervention. 4
• When glycemic targets are met with lifestyle measures and fetal growth is appropriate, additional surveillance beyond routine fetal movement monitoring is generally unnecessary. This avoids excessive interventions. [3][4]

Delivery Timing (Evidence Not Cited) – Omitted per instructions

Post‑partum Follow‑Up

• Screen for persistent diabetes or pre‑diabetes at 4–12 weeks postpartum using a 75‑g oral glucose tolerance test applying non‑pregnancy diagnostic criteria. Early detection facilitates timely management. 1
• Repeat screening every 1–3 years thereafter, as women with a history of gestational diabetes have a 50–70 % cumulative risk of developing type 2 diabetes over 15–25 years. Ongoing surveillance is essential for long‑term health. 1
• Encourage breastfeeding, which provides immediate nutritional and immunologic benefits to the infant and may confer longer‑term metabolic advantages to both mother and child. 1
• Review contraception options regularly for all women of child‑bearing age, including the postpartum period, to prevent unintended pregnancies and allow appropriate inter‑pregnancy intervals. 1

Team‑Based Care & Specialized Support

• Refer patients to specialized centers or interprofessional teams when available, given the complexity of insulin management during pregnancy. Multidisciplinary care improves outcomes. 1

Management of Gestational Diabetes Mellitus

Initial Management: Lifestyle Modifications

• The American Diabetes Association recommends that all women with gestational diabetes mellitus (GDM) should receive individualized medical nutrition therapy from a registered dietitian nutritionist (RDN) familiar with GDM management, with a diet providing adequate calories for fetal and maternal health while achieving glycemic control and appropriate gestational weight gain 6, 7.
• The National Academy of Medicine recommends that the diet must provide adequate calories for fetal and maternal health while achieving glycemic control and appropriate gestational weight gain 6, 7.
• Minimum daily requirements for women with GDM include 175g carbohydrates, 71g protein, and 28g fiber 8.
• Carbohydrates should be distributed across three small-to-moderate meals and two-to-four snacks throughout the day to limit postprandial glucose excursions 9.
• The American College of Obstetricians and Gynecologists recommends at least 150 minutes of moderate-intensity aerobic activity per week during pregnancy, preferably spread throughout the week 6, 7.

Glycemic Targets

• The Fifth International Workshop-Conference on Gestational Diabetes Mellitus recommends monitoring blood glucose aiming for targets of fasting glucose <95 mg/dL, one-hour postprandial glucose <140 mg/dL, and two-hour postprandial glucose <120 mg/dL 10, 8, 11.

Pharmacologic Therapy

• The American Diabetes Association recommends adding insulin if glycemic targets are not achieved with lifestyle modifications alone 10.
• Insulin is the preferred medication for treating hyperglycemia in GDM because it does not cross the placenta to a measurable extent 10, 9.
• The initial total daily insulin dose should be calculated as 0.7-1.0 units/kg of current weight, distributed as 40% basal insulin and 60% prandial insulin 9.

Telehealth and Team-Based Care

• The American Telemedicine Association recommends telehealth visits for pregnant people with GDM, which improve outcomes compared with standard in-person care 10.
• Team-based care through specialized centers or interprofessional team members is recommended by the American College of Obstetricians and Gynecologists 6, 7.

Common Pitfalls to Avoid

• The American College of Obstetricians and Gynecologists recommends not using metformin for polycystic ovary syndrome beyond the first trimester 10.
• The American Diabetes Association recommends not relying solely on A1C for monitoring, as it represents an average and may not capture physiologically relevant glycemic parameters in pregnancy 12.
• The American College of Obstetricians and Gynecologists recommends not delaying insulin initiation in women with poor glycemic control on lifestyle modifications 11.